NCT06672523

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

A Phase 1 Study to Evaluate the Mass Balance, Metabolism, Excretion, and Pharmacokinetics of [14C]-BMS-986504 (MRTX1719) in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of \[14C\]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.

Conditions

• Advanced Solid Tumors With Homozygous MTAP Deletion

Interventions

Type	Name	Description
DRUG	BMS-986504	Specified dose on specified days
DRUG	[14C]-BMS-986504	Specified dose on specified days

Timeline

• Start date: 2025-03-24
• Primary completion: 2026-04-20
• Completion: 2026-04-20
• First posted: 2024-11-04
• Last updated: 2026-04-09

Locations

3 sites across 2 countries: Hungary, Spain

Regulatory

• FDA-regulated drug study